Oncocross Co., Ltd. (KOSDAQ:382150)

Market Cap	107.80B
Revenue (ttm)	1.04B
Net Income (ttm)	-7.66B
Shares Out	12.02M
EPS (ttm)	-682.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,193
Average Volume	98,224
Open	8,960.00
Previous Close	8,870.00
Day's Range	8,800.00 - 9,020.00
52-Week Range	6,260.00 - 16,700.00
Beta	n/a
RSI	38.44
Earnings Date	Nov 10, 2025

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 382150

Financial Performance

In 2024, Oncocross's revenue was 1.07 billion, an increase of 1071.49% compared to the previous year's 91.52 million. Losses were -6.48 billion, 53.8% more than in 2023.